Boston Scientific Corp (BSX, Financial)(30-Year Financial) files its latest 10-K with SEC for the fiscal year ended on December 31, 2019. Boston Scientific Corp is a developer, manufacturer, and marketer of medical devices. The firm markets its devices to health-care professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales. Boston Scientific Corp has a market cap of $56.42 billion; its shares were traded at around $40.48 with a P/E ratio of 12.15 and P/S ratio of 5.48. Boston Scientific Corp had annual average EBITDA growth of 37.70% over the past five years. GuruFocus has detected 1 severe warning sign with Boston Scientific Corp. .
For the last quarter Boston Scientific Corp reported a revenue of $2.9 billion, compared with the revenue of $2.6 billion during the same period a year ago. For the latest fiscal year the company reported a revenue of $10.7 billion, an increase of 9.3% from last year. For the complete 30-year financial data, please go here.. For the last five years Boston Scientific Corp had an average revenue growth rate of 8.2% a year.
The reported diluted earnings per share was $3.33 for the year, an increase of 179.8% from previous year. The Boston Scientific Corp had a decent operating margin of 16.21%, compared with the operating margin of 16.89% a year before. The 10-year historical median operating margin of Boston Scientific Corp is 13.10%. The profitability rank of the company is 6 (out of 10).
At the current stock price of $40.48, Boston Scientific Corp is traded at 125.9% premium to its historical median P/S valuation band of $17.92. The P/S ratio of the stock is 5.48, while the historical median P/S ratio is 2.43. The stock lost 0.2% during the past 12 months.
CFO Recent Trades:
- EVP and CFO Daniel J. Brennan sold 20,463 shares of BSX stock on 02/13/2020 at the average price of $42.03. The price of the stock has decreased by 3.69% since.
Directors and Officers Recent Trades:
- EVP Pres MedSurg David A Pierce sold 1,511 shares of BSX stock on 02/19/2020 at the average price of $42.31. The price of the stock has decreased by 4.33% since.
- EVP & Pres, Interven Cardio Kevin J. Ballinger sold 1,757 shares of BSX stock on 02/19/2020 at the average price of $42.31. The price of the stock has decreased by 4.33% since.
- SVP, Manuf & Sup Chn John Bradley Sorenson sold 7,500 shares of BSX stock on 02/10/2020 at the average price of $42.48. The price of the stock has decreased by 4.71% since.
- EVP,Pres MedSurg David A Pierce sold 2,150 shares of BSX stock on 02/03/2020 at the average price of $42.17. The price of the stock has decreased by 4.01% since.
- SVP & Pres, Neuromodulation Maulik Nanavaty sold 9,623 shares of BSX stock on 02/03/2020 at the average price of $42.17. The price of the stock has decreased by 4.01% since.
For the complete 20-year historical financial data of BSX, click here.
